Vestibular Function Using Mitochondrial Antioxidant Therapy

• Status: Withdrawn
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine if supplementation with known mitochondrial antioxidants (alpha lipoic acid (ALA) and CoQ-10) will stabilize or improve vestibular function in older adults.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: The University of Texas Health Science Center at San Antonio
• Collaborator: National Institute on Aging (NIA)
• Treatments: Coenzyme Q10; Thioctic Acid; Ubiquinone

Criteria

Inclusion Criteria:

1. Community dwelling non-gender specific aged 65-90 years of age

2. For female subjects, confirm that they are post-menopausal

3. Diagnosed with vestibular dysfunction

4. Able to provide informed consent

5. Prepared to adhere to study drug regimen and attend all study visits

Exclusion Criteria:

1. Unable to provide informed consent

2. Allergy/sensitivity to the study drugs or any of their ingredients

3. Unable to adhere to study drug regimen or to attend study visits.

4. Current or past participation within a specified timeframe in another clinical trial, as warranted by the administration of this intervention.

5. Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.

6. Anticoagulant drugs: Anisindione (Miradon), dicumarol and warfarin (Coumadin and Jantoven)

7. Participants who are currently undergoing treatment with Insulin, Levothyroxine or chemotherapy drugs.

8. Participants who are undergoing treatment with theophylline.